PDF icon Download PDF
Semin Thromb Hemost 2019; 45(06): 629-637
DOI: 10.1055/s-0039-1693474
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients

Deborah Y. Park
1   Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio
,
Alok A. Khorana
2   Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio
› Author Affiliations
Further Information

Publication History

Publication Date:
26 July 2019 (online)

   Permissions and Reprints
Preview

Abstract

Venous thromboembolism (VTE) is a common complication of cancer occurring in up to one-fifth of cancer patients. The risk of VTE, which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is increased up to seven-fold in patients with cancer. While the indications and contraindications to treatment for VTE patients with cancer parallel to those patients without cancer, the treatment of VTE is challenging for cancer patients who are three-fold more likely to have VTE recurrence than patients without cancer and who are also at increased risk of bleeding. While anticoagulant therapy is recommended for most cancer patients with VTE, some patients may benefit from alternative interventions, such as thrombolysis, thromboembolectomy, or placement of an inferior vena cava (IVC) filter. Recent data support the use of direct oral anticoagulants (DOACs) for treatment of cancer-associated VTE in select cancer patients and for primary prevention of thromboembolism in high-risk cancer patients. Individualized decision-making, keeping in consideration the patient's risk for thrombotic and bleeding events is essential.

Keywords

cancer-associated venous thromboembolism - thrombosis - anticoagulation